natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that when Levonelle is taken together with certain interacting medicines (including the HIV medicine efavirenz and ritonavir, certain medicines for tuberculosis and epilepsy and herbal medicines containing St John's wort) the dose of Levonelle should be doubled. 
Euroopa Ravimiameti inimravimite komitee soovitas, et Levonelle võtmisel koos teatud koostoimivate ravimitega (sealhulgas HIV-i ravim efavirens ja ritonaviir, teatud tuberkuloosi- ja epilepsiaravimid ning naistepuna sisaldavad taimsed ravimid) tuleb Levonelle annust kahekordistada.
The CHMP recommended that women who use liver enzyme inducers should instead use a non-hormonal emergency contraceptive (i.e. a copper intrauterine device) which is not affected by liver enzyme inducing medicines. 
Inimravimite komitee soovitas, et naised, kes kasutavad maksaensüümide indutseerijaid, peaksid kasutama hoopis mittehormonaalset erakorralist kontratseptiivi (st vaske sisaldavat emakasisest vahendit), mida maksaensüüme indutseerivad ravimid ei mõjuta.
The application was based on a study that showed that blood levels of levonorgestrel were reduced by 
Taotlus põhines uuringul, mis näitas, et levonorgestreeli sisaldus veres vähenes ligikaudu 50% võrra naistel, kes võtsid efavirensit.
The CHMP noted that the reductions in blood levels of levonorgestrel seen with efavirenz were similar to those seen with other medicines (so-called liver enzyme inducers) that interact with levonorgestrel (including certain medicines for tuberculosis and epilepsy and herbal medicines containing St John's wort). 
Inimravimite komitee märkis, et efavirens vähendab levonorgestreeli sisaldust veres samamoodi kui teised ravimid (nn maksaensüümide indutseerijad), millel on koostoimed levonorgestreeliga (sealhulgas teatud tuberkuloosi- ja epilepsiaravimid ning naistepuna sisaldavad taimsed ravimid).
In order to ensure the correct use of Levonelle, the CHMP also recommended including advice on when to take a double dose on the medicine's outer carton as well as in the package leaflet. 
Levonelle õige kasutamise tagamiseks soovitas inimravimite komitee samuti lisada ravimi väliskarbile ja pakendi infolehele nõuande, millal võtta kahekordne annus.
In order to ensure the correct use of Levonelle, the CHMP recommended including advice on when to take a double dose on the medicine's outer carton as well as in the package leaflet. 
Levonelle õige kasutamise tagamiseks soovitas inimravimite komitee lisada ravimi väliskarbile ja pakendi infolehele nõuande, millal võtta kahekordne annus.
around 50% in women taking efavirenz, which is known to increase the activity of a particular liver enzyme (CYP3A4) which is involved in the breakdown of levonorgestrel. 
Efavirens suurendab maksaensüümi CYP3A4 aktiivsust, mis osaleb levonorgestreeli lagundamises.
EMA/353887/2016 
Levonelle ja sarnaste nimetuste teave (levonorgestreel, 1500 µg tabletid) EMA/353887/2016
The applicant requested a re-examination of the opinion. 
Taotleja soovis arvamuse taasläbivaatamist.
EMA/311892/2014 EMEA/H/C/002546 
23. mai 2014 EMA/405459/2014 EMEA/H/C/002546
What is Nerventra? 
Mis on Nerventra?
The company that applied for authorisation is Teva Pharma GmbH. 
Müügiluba taotles Teva Pharma GmbH.
If you are taking part in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you. 
Kui te osalete ravimi kliinilises uuringus ja vajate oma ravi kohta lisateavet, pöörduge palun arsti poole, kes teile ravi määras.
The CHMP opinion has no consequences on these trials. 
Inimravimite komitee arvamus neid uuringuid ei mõjuta.
In addition, the Committee was not convinced about the effectiveness of the company's proposed measures to prevent pregnancies in women who would take the medicine. 
Ka ei olnud komitee veendunud ettevõtte kavandatud rasestumisvastaste meetmete efektiivsuses, mille eesmärk oli vältida ravimit manustavate naiste rasestumist.
After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 22 May 2014. 
Pärast taotluse põhjenduste kaalumist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 22. mail 2014.
The expert group advised that the risks seen in animal studies could have been acceptable if a clear benefit was seen in clinical studies, although a strict pregnancy prevention scheme would have been required. 
Eksperdirühm soovitas, et loomuuringutes ilmnenud riskid oleksid vastuvõetavad, kui kliinilistes uuringutes täheldataks selget kasulikkust, kuigi vaja oleks ranget raseduse vältimise kava.
Nerventra is a medicine that contains the active substance laquinimod. 
Nerventra on ravim, mis sisaldab toimeainena lakvinimoodi.
What consequences does this refusal have for patients in clinical trials or compassionate use programmes? 
Kuidas mõjutab keeldumine praegu kliinilistes uuringutes või ravimi eriloa alusel kasutamise programmides osalevaid patsiente?
The exact way Nerventra works is not known, but it is believed to have a modulator effect on the immune system (the body's defences). 
Nerventra täpne toimemehhanism ei ole teada, kuid arvatavasti moduleerib see immuunsüsteemi (organismi kaitsesüsteemi).
On 23 January 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Nerventra, intended for the treatment of multiple sclerosis. 
23. jaanuaril 2014 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades hulgiskleroosi (sclerosis multiplex) raviks kasutatava ravimi Nerventa müügiloa andmisest keelduda.
Both studies lasted two years and the main measure of effectiveness was based on the reduction in the number of relapses per patient per year (what is known as the ‘annualised relapse rate'). 
Mõlemad uuringud kestsid kaks aastat ning efektiivsuse põhinäitaja aluseks oli patsiendi aastase relapsisageduse vähenemine.
Refusal of the marketing authorisation for Nerventra (laquinimod) 
Nerventra (lakvinimood) müügiloa andmisest keeldumine
At the time of the initial recommendation, the CHMP had concerns about results from animal studies showing a higher occurrence of cancers after long-term exposure to the medicine and noted that a similar long-term cancer risk could not be excluded in humans, especially when considering that the way the medicine works in the body is unclear. 
Esialgse soovituse ajal väljendas inimravimite komitee ettevaatlikkust seoses loomuuringute tulemustega, mis näitasid vähkkasvajate sagenemist pärast pikaajalist kokkupuudet ravimiga, ning märkis, et sarnast pikaajalist vähiriski ei saa välistada ka inimestel, eelkõige seepärast, et ravimi toimemehhanism organismis on ebaselge.
The company also provided results of two main studies in patients with relapsing-remitting MS. One of the studies involving 1,106 patients compared Nerventra with placebo (a dummy treatment), while the second study in 1,331 patients compared Nerventra with placebo and another medicine used to treat MS, interferon-beta 1a. 
Ühes uuringus (1106 patsienti) võrreldi Nerventrat platseeboga (näiv ravim) ning teises uuringus (1331 patsienti) võrreldi Nerventrat platseebo ja beeta-1a-interferooniga (samuti hulgiskleroosi ravim).
The CHMP noted that the effect of the medicine in preventing relapses was modest, and though its effect in slowing the worsening of disability was encouraging it still needed to be confirmed. 
Inimravimite komitee märkis, et ravimi toime relapside ennetamisel oli tagasihoidlik ning kuigi toime puude süvenemise aeglustamisel oli soodsam, on seda vaja veel kinnitada.
How is Nerventra expected to work? 
Milline on Nerventra eeldatav toime?
Refusal of the marketing authorisation for Nerventra (laquinimod) EMA/311892/2014 
Nerventra (lakvinimood) müügiloa andmisest keeldumine EMA/405459/2014
Therefore the Committee concluded that the benefits of Nerventra at the dose studied were not sufficient to outweigh the potential risks in patients with relapsing remitting MS and maintained its recommendation that the medicine be refused marketing authorisation. 
Nendel põhjustel järeldas komitee, et Nerventra kasulikkus uuritud annuses ei olnud piisav, et ületada võimalikke riske hulgiskleroosi relapseeruva-remiteeruva vormiga patsientidel, ning jäi varasema soovituse juurde ravimi müügiloa andmisest keelduda.
During the re-examination, the CHMP considered advice from an expert group in neurology. 
Taasläbivaatamise ajal arutas inimravimite komitee neuroloogia eksperdirühma arvamust.
The company informed the CHMP that there are a number of ongoing and planned clinical trials with Nerventra in patients with multiple sclerosis. 
Ettevõte teatas inimravimite komiteele, et praegu toimub ja kavatsetakse korraldada mitu Nerventra kliinilist uuringut hulgiskleroosiga patsientidel.
Nerventra was expected to be used to treat multiple sclerosis (MS), a disease in which the immune system malfunctions, causing inflammation that destroys the protective sheath around the nerves in the brain and spinal cord. 
Hulgiskleroos (sclerosis multiplex) on haigus, mille korral on immuunsüsteemi talitlus häiritud ja tekib põletik, milles hävib pea- ja seljaaju närve ümbritsev kaitsekest.
Nerventra was to be used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). 
Nerventrat kavatseti kasutada hulgiskleroosi relapseeruva-remiteeruva vormi raviks (kui patsiendil vahelduvad haiguse ägenemised (relapsid) ja sümptomiteta perioodid (remissioonid)).
There was also a possible risk (again from animal studies) of effects on the unborn baby when the medicine is taken by pregnant women. 
Ühtlasi oli olemas (samuti loomuuringute tulemuste järgi) võimalik lootekahjustuste risk, kui ravimit kasutatakse raseduse ajal.
The effects of Nerventra were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Nerventra toimet muude katsetega.
The CHMP noted that the risk could not be excluded with current data and that animal studies suggest that some of the harmful effects may be delayed and only seen later on in the child's life. 
Inimravimite komitee märkis, et praeguste andmete alusel ei saa riski välistada ja loomuuringute järgi võivad kahjulikud toimed avalduda alles hiljem.
control the inflammation and the damage to nerves, thus helping to reduce symptoms and the worsening of disability in patients with MS. 
Immuunsüsteemi moduleerides osaleb see eeldatavasti põletiku ja närvikahjustuste piiramisel, aidates seega leevendada hulgiskleroosiga patsientidel sümptomeid ja puude süvenemist.
What was Nerventra expected to be used for? 
Milleks kavatseti Nerventrat kasutada?
EMA/510659/2015 
Fexeric EMA/510659/2015
What is Fexeric and what is it used for? 
Mis on Fexeric ja milleks seda kasutatakse?
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom seejärel eritub organismist väljaheitega.
The full EPAR and risk management plan summary for Fexeric can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Fexerici kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The maximum dose is 12 tablets per day. 
Suurim annus on 12 tabletti ööpäevas.
A risk management plan has been developed to ensure that Fexeric is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Fexerici võimalikult ohutu kasutamine.
The overall safety profile was considered acceptable and comparable to other phosphate binders. 
Üldist ohutusprofiili peeti vastuvõetavaks ja võrreldavaks muude fosfaati
Fexeric is available as 1 g tablets. 
Fexerici turustatakse 1 g tablettidena.
Serious side effects were uncommon and mainly affected the gut and stomach. 
Rasked kõrvalnähud olid väga harvad ning mõjutasid peamiselt soolestikku ja magu.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Fexeric's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Inimravimite komitee otsustas, et Fexerici kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
In the second study, 149 patients who were not on dialysis received either Fexeric or placebo for 3 months. 
Teises uuringus osales 149 dialüüsi mittesaavat patsienti, kellele anti 3 kuu jooksul kas Fexerici või platseebot.
Blood-phosphate levels should be monitored regularly during treatment. 
Vere fosfaadisisaldust tuleb ravi ajal korrapäraselt jälgida.
What are the risks associated with Fexeric? 
Mis riskid Fexericiga kaasnevad?
In addition, the company that markets Fexeric will carry out a study to gain further information on the long-term safety of Fexeric, particularly in older patients. 
Lisaks viib Fexerici turustav ettevõte läbi uuringu, et saada lisateavet Fexerici pikaajalise ohutuse kohta, eelkõige eakamatel patsientidel.
What measures are being taken to ensure the safe and effective use of 
Mis meetmed võetakse, et tagada Fexerici ohutu ja efektiivne kasutamine?
The recommended starting dose is 3 to 6 tablets per day, taken in divided doses together with meals. 
Selle soovitatav algannus on 3-6 tabletti ööpäevas ning seda tuleb võtta jagatud annustena koos toiduga.
Both studies looked at the change in the amount of phosphate in the blood, measured in mg/dl. 
Mõlemas uuringus hinnati vere fosfaadisisalduse muutust, mõõdetuna väärtuses mg/dl.
In the first study, Fexeric was as effective as sevelamer carbonate, an approved medicine, in lowering phosphate levels in 359 patients with long-term kidney disease: after 12 weeks both treatments resulted in a reduction in phosphate levels of around 2 mg/dl. 
Esimeses uuringus oli Fexeric pikaajalise neeruhaigusega 359 patsiendi vere fosfaadisisalduse vähendamisel sama efektiivne kui sevelameerkarbonaat (heakskiidetud ravim): pärast 12-nädalast ravi andsid mõlemad ravimid tulemuseks fosfaadisisalduse vähenemise ligikaudu 2 mg/dl.
This is a summary of the European public assessment report (EPAR) for Fexeric. 
See on ravimi Fexeric Euroopa avaliku hindamisaruande kokkuvõte.
The most common side effects with Fexeric (which may affect more than 1 in 10 people) are changes in bowel movements (diarrhoea or constipation) and discoloured faeces. 
Fexerici kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on sooletegevuse muutused (kõhulahtisus või kõhukinnisus) ja väljaheite värvuse muutus.
It is not intended to provide practical advice on how to use Fexeric. 
Hindamisaruandes ei anta Fexerici kasutamise praktilisi nõuandeid.
This prevents the phosphate from being absorbed into the body and helps to keep down the phosphate levels in the blood. 
See takistab fosfaadi imendumist organismi ning aitab hoida vere fosfaadisisalduse väiksena.
When taken with meals, the iron contained in Fexeric binds to phosphate from food in the gut, forming a compound that is then eliminated in the stools. 
Koos toiduga võtmisel seondub Fexericis sisalduv raud seedetraktis toidus sisalduva fosfaadiga ja moodustab ühendi, mis
The study showed that blood-phosphate levels fell on average by 0.7 mg/dl with Fexeric compared with 0.3 mg/dl with placebo. 
Uuringust nähtus, et Fexericiga langes vere fosfaadisisaldus keskmiselt 0,7 mg/dl ning
Fexeric is a medicine used to control hyperphosphataemia (high levels of phosphate in the blood) in adults with long-term kidney disease. 
Fexeric on ravim, mida kasutatakse hüperfosfateemia (vere suur fosfaadisisaldus) reguleerimiseks pikaajalise neeruhaigusega täiskasvanutel.
Fexeric must not be used in patients with low blood-phosphate levels, patients who have severe problems with the stomach and gut (such as bleeding from the gut), and those with iron accumulation disorders such as haemochromatosis. 
Fexerici ei tohi kasutada patsientidel, kelle vere fosfaadisisaldus on väike, kellel on raske mao- või soolehaigus (näiteks sooleverejooks) ning kellel on raua kogunemise häired, näiteks hemokromatoos.
Patients should keep to their prescribed low 
Patsiendid peavad järgima neile määratud väikese fosfaadisisaldusega dieete.
What benefits of Fexeric have been shown in studies? 
Milles seisneb uuringute põhjal Fexerici kasulikkus?
A build-up of phosphate leads to hyperphosphataemia and in the long-term can cause complications such as heart 
Fosfaadi kogunemisel tekib hüperfosfateemia, mis võib aja jooksul tekitada tüsistusi, näiteks südame- ja luuhaigusi.
Patients with severe kidney disease have difficulty eliminating phosphate from their bodies. 
Raske neeruhaigusega patsientide organism ei suuda fosfaati väljutada.
For practical information about using Fexeric, patients should read the package leaflet or contact their 
Kui vajate Fexerici kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti
It contains the active substance ferric citrate coordination 
See sisaldab toimeainena raud(III)tsitraadi koordinatiivset
The active substance in Fexeric, ferric citrate coordination complex, is a phosphate binder. 
Fexerici toimeaine raud(III)tsitraadi koordinatiivne ühend seob fosfaate.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Fexeric, including the appropriate precautions to be followed by healthcare 
Selle alusel lisati Fexerici omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
For more information about treatment with Fexeric, read the package leaflet (also part of the EPAR) or contact 
Kui vajate Fexericiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
The CHMP considered that Fexeric is effective at controlling blood-phosphate levels in patients with long-term kidney disease, whether they are on dialysis or not. 
Inimravimite komitee arvamuse kohaselt on Fexeric efektiivne vere fosfaadisisalduse reguleerimisel pikaajalise neeruhaigusega patsientidel, kes saavad või ei saa dialüüsi.
The medicine can only be obtained with a prescription. 
Fexeric on retseptiravim.
Fexeric was shown to be effective at controlling blood-phosphate levels in 2 main studies in patients with long-term kidney disease and hyperphosphataemia. 
Kahes põhiuuringus, kus osalesid pikaajalise neeruhaiguse ja hüperfosfateemiaga patsiendid, tõendati, et Fexeric on vere fosfaadisisalduse reguleerimisel efektiivne.
20 January 2009 
20. jaanuar 2009
What is Sliwens? 
Mis on Sliwens?
The main measures of effectiveness were based on the amount of time the patients spent awake after they had first fallen asleep and improvements in the quality of sleep over the first four to 12 weeks of treatment. 
Efektiivsuse põhinäitajad põhinesid ajal, kui kaua oli patsient pärast esmast uinumist ärkvel, ja unekvaliteedi ravi esimese 4-12 nädala jooksul toimunud paranemisel.
It was to be available as tablets. 
Seda kavatseti turustada tablettidena.
The company presented results of four main studies involving over 3,000 adults who had difficulty staying asleep. 
Ettevõte esitas nelja põhiuuringu tulemused (uuringutes osales üle 3000 täiskasvanu, kellel oli raskusi une säilitamisega).
Withdrawal of marketing authorisation application for Sliwens (eplivanserin) EMA/23705/2010 
Müügiloa taotluse tagasivõtmise teave Sliwens (eplivanseriin) EMA/139260/2010
Withdrawal of marketing authorisation application for Sliwens (eplivanserin) 
Müügiloa taotluse tagasivõtmise teave Sliwens (eplivanseriin)
There was also a lack of information comparing the long-term use of Sliwens with placebo. 
Samuti puudus Sliwensi ja platseebo pikaajalise võrdleva kasutamise teave.
It was to be used in patients who have difficulty staying asleep. 
Ravimit kavatseti kasutada patsientidel, kellel on raskusi une säilitamisega.
Sliwens is a medicine that contains the active substance eplivanserin. 
Sliwens on ravim, mille toimeaine on eplivanseriin.
The company informed the CHMP that there were no consequences for patients in clinical trials or compassionate use, since all ongoing clinical trials have been discontinued. 
Ettevõte teatas inimravimite komiteele, et praegu kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda, sest kõik toimunud kliinilised katsed on peatatud.
The active substance in Sliwens, eplivanserin, is a 5-hydroxytryptamine receptor antagonist. 
Sliwensi toimeaine eplivanseriin on 5-hüdroksütrüptamiini (serotoniini) retseptori antagonist.
The studies compared Sliwens with placebo (a dummy treatment). 
Uuringud võrdlesid Sliwensit platseeboga (näiv ravim).
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Sliwens could not have been approved. 
Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjuseid ettevaatlikkuseks ning oli esialgsel seisukohal, et Sliwensi müügiluba ei saa anda.
It blocks receptors in the brain called 5-hydroxytryptamine type 2 receptors, which are involved in regulating the daily cycle of being asleep and being awake. 
Eplivanseriin blokeerib ajus 5-hüdroksütrüptamiini II tüüpi retseptorid, mis osalevad ööpäevase une- ja ärkvelolekurütmi reguleerimisel.
By blocking these receptors, eplivanserin was expected to modify the sleep-wake cycle, helping people with long-term insomnia to stay asleep. 
Retseptorite blokeerimisega eeldati, et eplivanseriin muudab une- ja ärkvelolekurütmi, aidates kroonilise unetusega patsientidel säilitada und.
On 18 December 2009, Sanofi-Aventis officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Sliwens, for use in adults with chronic (long-term) insomnia who have difficulty staying asleep. 
18. detsembril 2009 teatas Sanofi-Aventis ametlikult inimravimite komiteele oma otsusest võtta tagasi ravimi Sliwens müügiloa taotlus.
The effects of Sliwens were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Sliwensi toimet muude katsetega.
The CHMP considered the effect of Sliwens on sleep to be small. 
Inimravimite komitee pidas Sliwensi mõju unele väikeseks.
study involving 283 adults compared Sliwens with lormetazepam (another medicine used to treat insomnia) looked at how sleepy the patients were the morning after taking Sliwens. 
lormetatsepaamiga (samuti unetuse ravim) ja vaadeldi, kui unised olid Sliwensit võtnud patsiendid hommikul.
How was Sliwens expected to work? 
Milline on Sliwensi eeldatav toime?
The Committee was also concerned about the risk of diverticulitis (inflammation in little sacs or pouches in the intestines) in patients taking the medicine. 
Komitee väljendas ettevaatlikkust ka põhjusel, et ravimit võtvatel patsientidel esineb divertikuliidi (soolesopististe põletiku) risk.
Sliwens was expected to be used in adults with long-term insomnia (difficulty sleeping). 
Sliwensit kavatseti kasutada kroonilise (pikaajalise) unetuse raviks täiskasvanutel.
What was Sliwens expected to be used for? 
Milleks kavatseti Sliwensit kasutada?
Zeletavská 1525/1 
Želetavská 1525/1
6th floor, ap 37+Sofia Bulgaria 
6th floor, ap 37+Sofia
AGUETTANT 1, rue Alexander Fleming 
Prantsusmaa AGUETTANT 1, rue Alexander Fleming
Luxembourg Baxter S.A. Boulevard René Branquart 80 
Luksemburg Baxter S.A. Boulevard René Branquart 80
Zelezna cesta 18 1000 Ljubljana Slovenija 
Železna cesta 18 1000 Ljubljana Slovenija
BAXTER HELLAS Ltd, Metsovou 3, Neo Irakleion 14121, Athens Greece 
BAXTER HELLAS Ltd, Metsovou 3, Neo Irakleion 14121, Athens
VIOSER SA, 9th Km National Highway TrikalaLarissis, 
9th Km National Highway TrikalaLarissis,